Interleukin 17A (IL-17A), the effector cytokine of Th17 cells, has emerged as a promising therapeutic target in immune and chronic inflammatory diseases, including hypertension and chronic kidney disease (Caillon and Schiffrin, 2016; Solak et al., 2016; Cortvrindt et al., 2017). This evidence concerns the gene IL17A and hypertensive disorder.